GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » EPS without NRI

Eterna Therapeutics (Eterna Therapeutics) EPS without NRI : $-4.05 (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics EPS without NRI?

Eterna Therapeutics's earnings per share without non-recurring items for the three months ended in Dec. 2023 was $-1.15. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.05.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Eterna Therapeutics's EPS without NRI or its related term are showing as below:

ERNA' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.8   Med: -4.8   Max: -4.8
Current: -4.8

ERNA's 3-Year EPS without NRI Growth Rate is ranked worse than
62.26% of 1301 companies
in the Biotechnology industry
Industry Median: 5.1 vs ERNA: -4.80

Eterna Therapeutics's EPS (Diluted) for the three months ended in Dec. 2023 was $-1.14. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.08.

Eterna Therapeutics's EPS (Basic) for the three months ended in Dec. 2023 was $-1.14. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-4.08.


Eterna Therapeutics EPS without NRI Historical Data

The historical data trend for Eterna Therapeutics's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics EPS without NRI Chart

Eterna Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
EPS without NRI
-3.51 -24.59 -8.99 -4.05

Eterna Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.43 -1.05 -0.83 -1.03 -1.15

Competitive Comparison of Eterna Therapeutics's EPS without NRI

For the Biotechnology subindustry, Eterna Therapeutics's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eterna Therapeutics's PE Ratio without NRI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's PE Ratio without NRI falls into.



Eterna Therapeutics EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.05

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eterna Therapeutics  (NAS:ERNA) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Eterna Therapeutics EPS without NRI Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Eterna Therapeutics (Eterna Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Executives
Dorothy J Clarke director C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder director C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft 10 percent owner 4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern 10 percent owner
Nicholas Jason Singer director 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore director 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson officer: Chief Financial Officer 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel officer: Interim President and CEO 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman director TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536

Eterna Therapeutics (Eterna Therapeutics) Headlines

From GuruFocus

Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President

By Stock market mentor Stock market mentor 01-04-2023